Pharmacogenomics of clopidogrel: evidence and perspectives.

Abstract excerpt

Clopidogrel has become the mainstay oral antiplatelet regimen to prevent recurrent ischemic events after acute coronary syndromes or stent placement. However, there is marked interindividual variability in the antiplatelet effects of clopidogrel, and a reduced response to this drug may be a risk factor for ischemic complications. Pharmacogenomic analyses, including candidate-gene and genome-wide association...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Clopidogrel
• Share to Aryl Hydrocarbon Hydroxylases
• Share to Aryldialkylphosphatase